UXN Co., Ltd., a South Korean biomedical company listed on the KONEX (Korea New Exchange) for startups and SMEs, specializes in the development of enzyme-free continuous glucose monitoring (CGM) technology. Its proprietary mesoporous platinum electrode sensor offers high sensitivity, long lifespan, calibration-free operation, and low interference. The product series has completed human clinical trials and is currently undergoing regulatory approval by Korea's Ministry of Food and Drug Safety (MFDS). UXN plans to expand into China, the United States, and Europe, driving global commercialization and building an ecosystem for remote diabetes management and wearable medical devices.